Outcomes of systemic therapy for advanced triple-negative breast cancer: A single centre experience.

CONCLUSIONS: The observed response rates are consistent with literature. However, PFS is short, and early consideration of clinical trials can be justified in these patients. PMID: 29698926 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/29698926?dopt=Abstract

Source: Breast - April 23, 2018 Category: Cancer & Oncology Authors: Battisti NML, Okonji D, Manickavasagar T, Mohammed K, Allen M, Ring A Tags: Breast Source Type: research